Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Servier Completes the Acquisition of Symphogen
Details : As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 06, 2020
Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline
Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 04, 2020
Reset All
